Sequent Scientific Ltd announced Q4 FY25 financial results with revenues of ₹4,017 million (up 11.2%) and EBITDA of ₹569 million (up 38.7%), and for FY25 total revenues were ₹15,514 million (up 13.3%) with EBITDA at ₹1,993 million (up 86.6%). The company is also proceeding with its merger with Viyash Life Sciences.